Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Immunocore Limited has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 3 examiners and 3 art units, indicating that the current prosecution workload is spread across separate examination assignments rather than concentrated in one technical unit.
CHEONG, CHEOM-GIL is the busiest examiner, with 1 pending matter. Counsel can therefore organize the docket by examiner and art unit, while treating each action as a distinct prosecution track.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 2 | 59.8% | +41.3% |
| CHEONG, CHEOM-GIL | 1 | 64.8% | +52.7% |
| XIAO, YAN | 1 | 67.4% | +52.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18757296 | HIV Specific Binding Molecules and Uses Thereof | CHEONG, CHEOM-GIL | — |
| 18489854 | DOSING REGIMEN FOR GP100-SPECIFIC TCR - ANTI-CD3 SCFV FUSION PROTEIN | SKELDING, ZACHARY S | — |
| 18064180 | Peptides | XIAO, YAN | — |
| 17929682 | BIFUNCTIONAL POLYPEPTIDES | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1645 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18757296 | HIV Specific Binding Molecules and Uses Thereof | CHEONG, CHEOM-GIL | 1645 | — | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18489854 | DOSING REGIMEN FOR GP100-SPECIFIC TCR - ANTI-CD3 SCFV FUSION PROTEIN | SKELDING, ZACHARY S | 1644 | DP | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18064180 | Peptides | XIAO, YAN | 1642 | §102§112DP | Final Rejection | — | Pending | Dec 09, 2022 |
| 17929682 | BIFUNCTIONAL POLYPEPTIDES | SKELDING, ZACHARY S | 1644 | §103 | Non-Final OA | — | Pending | Sep 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunocore Limited has 4 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
Zachary S Skelding has the most, with 2 of Immunocore Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.